Published March 19, 2021 | Version v1
Journal article Open

ACUTE PER ORAL TOXICITY OF TILMICOSIN – SUBSTANCE "BIOVET" AD IN WHITE RATS (FISCHER – 344)

Authors/Creators

  • 1. University of Forestry, Sofia, Bulgaria

Contributors

  • 1. University of Forestry

Description

The acute oral toxicity of Tilmicosin – a substance "Biovet" in rats, was studied. 42 male white rats, Fischer 344 line, weighing 160–180 g, were treated with 10% aqueous solution of Tilmicosin phosphate Biovet using a gastric tube. For each dose (500, 1000, 1500, 2000, 2500, 3000 and 3500 mg/body weight), 6 were treated once. Rats, which were monitored for 7 days, taking into account the clinical picture of their intoxication and mortality. Based on the Litchfield-Wilcoxon method used in the test, an average lethal dose of LD50 2200 (2860 ÷ 1692) mg/body weight (p = 0.05) and relatively lethal doses of LD16 = 1142 and LD84 = 3256 mg/body weight were determined, which classify the product as low toxic. The results regarding the acute toxicity of Tilmicosin when administered orally to white rats con-firm the studies conducted with the original Eli Lilly product that Tilmicosin has low toxicity when ad-ministered for oral use – LD50 > 2000 mg / body weight (Piroozi, K.S. et al. 1993).

Files

vol-6-1_2021-44-48.pdf

Files (496.3 kB)

Name Size Download all
md5:94b88848d263ef9ef3fe3ccfced53032
496.3 kB Preview Download

Additional details

Related works

Is documented by
Journal article: https://scij-tmvm.com/vol./vol.6/1/vol-6-1_2021-44-48.pdf (URL)

References

  • Georgiev, B., Vangelov, S., Kostadin, L., Bankova, R., Hristoskova, E., Arnaudova, E. (2010). Vet-erinary Pharmacological Handbook. Sofia
  • Melnikov, N. N. (1987). Pesticides. Moscow "Chemistry", 20–21.
  • Melnikov, N. N. (1987). Pesticides. Moscow "Chemistry", 20–21.
  • Barragry, T. B. (1994). Aminoglycosides, macrolides, and lincosamides. In: Veterinary Drug Ther-apy, 241–263, Williams & Wilkins, Philadelphia, USA.
  • Bureau Report. (1995). Suspected drug adverse reactions reported to The Bureau of Veterinary Drugs. Can. Vet. J., 36, 246–49.
  • Christodoulopoulos G, Warnick L. D, Papaioannou N, Fthenakis, G. C. (2002). Tilmicosin admin-istration to young lambs with respiratory infection: Safety and efficacy considerations. J Vet Phar-macol Ther, 25:393–397.
  • Gheith, A. El-Mahmoudy, A. Elmajdoub & S. Awidat. (2015). Pharmacovigilance of Tilmicosin in Mice. Acta Scientiae Veterinariae. 43: 1318.
  • Jordan, W. H, R. A. Byrd, R. L Cochrance, G. K. Hanasomo, J. A. Hoyt, B. W. Mainq, R. D. Mey-erhoff, R. D. Sarazan. (1993). A review of the toxicology of the antibiotic Micotil 300. Veterinary and Human Toxicology, 35, 151–158.
  • Jordan F. T., Forrester C. A., Hodge A. and Reeve-John-Son L.G. (1999). The comparison of an aqueous preparation of tilmicosin with tylosin in the treatment of Mycoplasma gallisepticum infec-tion of turkey poults. Avian Dis., 43, 521–525.
  • Kart A, Yapar K, Karapehlivan M, Citil M. (2007). The possible protective effect of L-carnitine on tilmicosin-induced cardiotoxicity in mice. J Vet Med a Physiol Pathol Clin Med, 54:144–146
  • Litchfield Y. Y., F. Wilcoxon. (1949). Asimplified method of evaluating dose – effective experiment. J. Pharm. Exp. Therap., 96, 99–113
  • Mateusen B., Maes D., Hoflack G., Verdonck M. & De Kruif A. (2001). A comparative study of the preventive use of tilmicosin phosphate (Pulmotil premixョ) and Mycoplasma hyopneumoniae vac-cination in a pig herd with chronic respiratory disease. Journal of Veterinary Medicine, Series B. 48(10): 733–741.
  • McGuigan, M. A. (1994). Human exposures to tilmicosin. Vet. Hum. Toxicol, 36, 306–308.
  • McKay S. G., Morck D. W., Merril J. K., Olson M. E., Chan S. C. and Pap K. M. (1996). Use of tilmicosin for treatment of pasteurellosis in rabbits. Am. J. Vet. Res., 57, 1180–1184.
  • Modric, S., A. I. Webb, H. Derendorf. (1998). Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J. Vet. Pharmacol. Therap, 21, 444–452.
  • Piroozi, K. S., Keaton, M. J., & Jordan, W. H. (1993). The acute toxicity of tilmicosin administered orally to Fischer 344 rats. Unpublished study No. R21493 from Lilly Research Laboratories.Sub-mitted to WHO by Lilly, Basingstoke, UK.
  • Ramadan, A. (1997). Pharmacokinetics of tilmicosin in serum and milk of goats. Res. Vet. Sci., 62, 48–50.
  • Roberts, G. (1999). Inchem. 878 Tilmicosin. WHO Food Additives Series 38, 1–16.
  • Wakambayachi, K., S. Yamada. (1972). Effect of several macrolide antibiotics of blood pressure of dog. Japanes Journal of Pharmacology, 22, 799.
  • Womble A., Giguère S., Murthy Y., Cox C. & Obare E. (2006). Pulmonary disposition of tilmicosin in foals and in vitro activity against Rhodococcus equi and other common equine bacterial patho-gens. Journal of veterinary pharmacology and therapeutics. 29 (6): 561–568.
  • Yazar, E., E. Ozterkin, A. Sivrikaya, R. Col, M. Elmas, A.L. Bas. (2004). Effect of Different Doses of Tilmicosin on Malondialdehyde and Glutathione Concentrations in Mice. Acta Vet. Brno, 73, 69–72.